Opaleye Management Inc.: insider trades.
Opaleye Management Inc. reported 47 non-derivative transactions on 19 SEC ownership filings in Q3 2026: 38 open-market purchases ($7.6M) and 9 sales ($6.9M), across 4 companies.
- Transactions
- 47
- Purchases (P)
- 38
- Sales (S)
- 9
- Companies
- 4
- Name as filed
- Opaleye Management Inc.
Companies
| Company | Relationship | Transactions |
|---|---|---|
| Sol-Gel Technologies Ltd. (SLGL) | TenPercentOwner | 21 |
| Alpha Cognition Inc. (ACOG) | TenPercentOwner | 12 |
| Eton Pharmaceuticals, Inc. (ETON) | TenPercentOwner | 9 |
| Grace Therapeutics, Inc. (GRCE) | TenPercentOwner | 5 |
Transactions
| Date | Company | Code | Shares | Price | Owned after | Filing |
|---|---|---|---|---|---|---|
| 2026-09-25 | Alpha Cognition Inc. | P | 13,426 | $8.47 | 3,203,904 | Form 4 |
| 2026-09-24 | Alpha Cognition Inc. | P | 18,337 | $8.57 | 3,190,478 | Form 4 |
| 2026-09-23 | Grace Therapeutics, Inc. | P | 5,318 | $2.1 | 2,855,318 | Form 4 |
| 2026-09-21 | Grace Therapeutics, Inc. | P | 9,771 | $2.1 | 2,850,000 | Form 4 |
| 2026-09-16 | Alpha Cognition Inc. | P | 27,141 | $8.4 | 3,172,141 | Form 4 |
| 2026-09-16 | Alpha Cognition Inc. | P | 53,029 | $8.57 | 3,145,000 | Form 4 |
| 2026-09-15 | Alpha Cognition Inc. | P | 3,375 | $8.54 | 3,091,971 | Form 4 |
| 2026-09-14 | Alpha Cognition Inc. | P | 40,373 | $8.7 | 3,088,596 | Form 4 |
| 2026-09-11 | Sol-Gel Technologies Ltd. | P | 1,493 | $65.95 | 540,000 | Form 4 |
| 2026-09-10 | Sol-Gel Technologies Ltd. | P | 1,631 | $66.8 | 538,507 | Form 4 |
| 2026-09-09 | Grace Therapeutics, Inc. | P | 5,836 | $2.09 | 2,775,229 | Form 4 |
| 2026-09-09 | Sol-Gel Technologies Ltd. | P | 3,097 | $68.71 | 536,876 | Form 4 |
| 2026-09-08 | Grace Therapeutics, Inc. | P | 9,393 | $2.1 | 2,769,393 | Form 4 |
| 2026-09-08 | Sol-Gel Technologies Ltd. | P | 471 | $69.37 | 533,779 | Form 4 |
| 2026-09-08 | Sol-Gel Technologies Ltd. | P | 3,390 | $68.74 | 533,308 | Form 4 |
| 2026-09-04 | Sol-Gel Technologies Ltd. | P | 918 | $69.52 | 527,818 | Form 4 |
| 2026-09-04 | Sol-Gel Technologies Ltd. | P | 2,100 | $68.98 | 529,918 | Form 4 |
| 2026-09-02 | Sol-Gel Technologies Ltd. | P | 900 | $68.95 | 526,900 | Form 4 |
| 2026-09-01 | Sol-Gel Technologies Ltd. | P | 783 | $69.52 | 526,000 | Form 4 |
| 2026-08-31 | Sol-Gel Technologies Ltd. | P | 5,000 | $68.24 | 525,000 | Form 4 |
| 2026-08-31 | Sol-Gel Technologies Ltd. | P | 217 | $69.1 | 525,217 | Form 4 |
| 2026-08-28 | Sol-Gel Technologies Ltd. | P | 5,000 | $68.81 | 520,000 | Form 4 |
| 2026-08-28 | Sol-Gel Technologies Ltd. | P | 20,113 | $68.42 | 515,000 | Form 4 |
| 2026-08-28 | Sol-Gel Technologies Ltd. | P | 10,000 | $71.4 | 494,887 | Form 4 |
| 2026-08-14 | Grace Therapeutics, Inc. | P | 11,608 | $2.09 | 2,760,000 | Form 4 |
| 2026-08-12 | Sol-Gel Technologies Ltd. | P | 951 | $71.5 | 494,887 | Form 4 |
| 2026-08-03 | Alpha Cognition Inc. | P | 50,000 | $8 | 3,048,223 | Form 4 |
| 2026-07-31 | Alpha Cognition Inc. | P | 2,900 | $7.92 | 2,998,223 | Form 4 |
| 2026-07-24 | Alpha Cognition Inc. | P | 130 | $7.9 | 2,995,323 | Form 4 |
| 2026-07-23 | Alpha Cognition Inc. | P | 49,849 | $7.8 | 2,995,193 | Form 4 |
| 2026-07-22 | Alpha Cognition Inc. | P | 10,000 | $7.83 | 100,000 | Form 4 |
| 2026-07-22 | Alpha Cognition Inc. | P | 140,237 | $7.83 | 2,945,344 | Form 4 |
| 2026-07-14 | Eton Pharmaceuticals, Inc. | S | 13,315 | $37.54 | 40,000 | Form 4/A |
| 2026-07-14 | Eton Pharmaceuticals, Inc. | S | 15,000 | $37.54 | 2,665,000 | Form 4/A |
| 2026-07-14 | Eton Pharmaceuticals, Inc. | S | 15,000 | $37.54 | 2,665,000 | Form 4 |
| 2026-07-14 | Eton Pharmaceuticals, Inc. | S | 13,315 | $37.54 | 40,000 | Form 4 |
| 2026-07-14 | Sol-Gel Technologies Ltd. | P | 920 | $73.43 | 493,936 | Form 4 |
| 2026-07-13 | Sol-Gel Technologies Ltd. | P | 775 | $73.89 | 493,016 | Form 4 |
| 2026-07-10 | Sol-Gel Technologies Ltd. | P | 229 | $73.95 | 492,241 | Form 4 |
| 2026-07-08 | Sol-Gel Technologies Ltd. | P | 300 | $73.69 | 492,012 | Form 4 |
| 2026-07-07 | Eton Pharmaceuticals, Inc. | S | 20,000 | $38.37 | 2,680,000 | Form 4 |
| 2026-07-07 | Eton Pharmaceuticals, Inc. | S | 6,685 | $38.37 | 53,315 | Form 4 |
| 2026-07-06 | Eton Pharmaceuticals, Inc. | S | 10,000 | $38 | 2,700,000 | Form 4 |
| 2026-07-02 | Eton Pharmaceuticals, Inc. | S | 25,000 | $37.39 | 60,000 | Form 4 |
| 2026-07-02 | Eton Pharmaceuticals, Inc. | S | 65,000 | $37.39 | 2,710,000 | Form 4 |
| 2026-07-02 | Sol-Gel Technologies Ltd. | P | 1,400 | $71.97 | 491,712 | Form 4 |
| 2026-07-01 | Sol-Gel Technologies Ltd. | P | 312 | $71.99 | 490,312 | Form 4 |
Questions
What stock did Opaleye Management Inc. buy or sell?
Opaleye Management Inc. reported 47 non-derivative transactions on 19 SEC ownership filings in Q3 2026: 38 open-market purchases ($7.6M) and 9 sales ($6.9M), across 4 companies.
Is Opaleye Management Inc. the same person as other filers with this name?
This page covers SEC CIK 1595855 only. The SEC assigns each reporting owner a CIK, and people with the same name have different CIKs.
Source: SEC Insider Transactions Data Sets, Q3 2026. Reported as filed; we do not assess intent, performance or compliance. All filings for this CIK on SEC.gov.
Plain-text version for agents and LLMs: /insiders/opaleye-management-inc-1595855.md
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Securities and Exchange Commission. Data is reproduced from public SEC filings and datasets. Not investment advice.